Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study

BACKGROUND: Current guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with left-sided RAS wild type (RASwt) metastatic colorectal cancer (mCRC). However, there are no guideline recommendations specific to tumor si...

Descripción completa

Detalles Bibliográficos
Autores principales: Archwamety, Anita, Teeyapun, Nattaya, Siripoon, Teerada, Poungvarin, Naravat, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Akewanlop, Charuwan, Korphaisarn, Krittiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886166/
https://www.ncbi.nlm.nih.gov/pubmed/35242708
http://dx.doi.org/10.3389/fonc.2022.813009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886166/
https://www.ncbi.nlm.nih.gov/pubmed/35242708
http://dx.doi.org/10.3389/fonc.2022.813009

Ejemplares similares